The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...
Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...
Merck shares tumbled Tuesday morning after the drugmaker's soft outlook outweighed fourth-quarter revenue and adjusted profits topping expectations.
19hon MSN
MRK provided 2025 adjusted EPS guidance of $8.88 to $9.03, while the giant drugmaker expects sales of $64.1 billion to $65.6 ...
Stocks were rising Tuesday even as China retaliated against new U.S. tariffs by unveiling levies on certain American goods ...
Investor's Business Daily on MSN15h
Merck Stock Plummets 9% As Gardasil Dynamics, 2025 Guidance Weigh On SharesInvestors hammered Merck stock Tuesday after the company beat fourth-quarter expectations, but delivered a light 2025 outlook.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback